Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.

Patients with advanced stage invasive cervical cancer (CC) exhibit highly complex genomic alterations and respond poorly to conventional treatment protocols. In our efforts to understand the molecular genetic basis of CC, we examined the role of Fanconi Anemia (FA)-BRCA pathway. Here, we show that FANCF gene is disrupted by either promoter hypermethylation and/or deregulated gene expression in a majority of CC. Inhibition of DNA methylation and histone deacetylases induces FANCF gene re-expression in CC cell lines. FANCF-deregulated CC cell lines also exhibit a chromosomal hypersensitivity phenotype after exposure to an alkylating agent, a characteristic of FA patients. We also show the involvement of BRCA1 gene by promoter hypermethylation or down-regulated expression in a small subset of CC patients. Thus, we have found inactivation of genes in the FA-BRCA pathway by epigenetic alterations in a high proportion of CC patients, suggesting a major role for this pathway in the development of cervical cancer. Thus, these results have important implications in understanding the molecular basis of CC tumorigenesis and clinical management in designing targeted experimental therapeutic protocols.

[1]  Andrea Califano,et al.  SPLASH: structural pattern localization analysis by sequential histograms , 2000, Bioinform..

[2]  J. Herman,et al.  Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. , 2003, Cancer cell.

[3]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[4]  E. G. Friedrich,et al.  Association of Fanconi's anemia and squamous-cell carcinoma of the lower female genital tract with condyloma acuminatum. A report of two cases. , 1984, The Journal of reproductive medicine.

[5]  Andrea Califano,et al.  Analysis of Gene Expression Microarrays for Phenotype Classification , 2000, ISMB.

[6]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[7]  A. D’Andrea,et al.  A novel diagnostic screen for defects in the Fanconi anemia pathway. , 2002, Blood.

[8]  Hans Joenje,et al.  The emerging genetic and molecular basis of Fanconi anaemia , 2001, Nature Reviews Genetics.

[9]  Marianne Berwick,et al.  A 20-year perspective on the International Fanconi Anemia Registry (IFAR). , 2003, Blood.

[10]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[11]  R. Hruban,et al.  Fanconi anemia gene mutations in young-onset pancreatic cancer. , 2003, Cancer research.

[12]  G. Evans,et al.  Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. , 2000, Cancer research.

[13]  M. Mansukhani,et al.  Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome , 2003, Molecular Cancer.

[14]  Bhuvanesh Singh,et al.  Comprehensive molecular cytogenetic characterization of cervical cancer cell lines , 2003, Genes, chromosomes & cancer.

[15]  R. Chaganti,et al.  Allelotype analysis of cervical carcinoma. , 1994, Cancer research.

[16]  J. Herman,et al.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. , 2002, Cancer research.

[17]  Mei Liu,et al.  Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival , 2004, Oncogene.

[18]  S. Waggoner Cervical cancer , 2003, The Lancet.

[19]  S. Seal,et al.  Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. , 2003, Cancer research.